Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes

Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2021-11, Vol.40 (44), p.6258-6272
Hauptverfasser:	Lebedev, Timofey, Vagapova, Elmira, Spirin, Pavel, Rubtsov, Petr, Astashkova, Olga, Mikheeva, Alesya, Sorokin, Maxim, Vladimirova, Uliana, Suntsova, Maria, Konovalov, Dmitry, Roumiantsev, Alexander, Stocking, Carol, Buzdin, Anton, Prassolov, Vladimir
Format:	Artikel
Sprache:	eng
Schlagworte:	13/21 13/31 13/95 14/10 38/39 631/67/2332 631/67/69 Analysis Antimitotic agents Antineoplastic agents Antineoplastic drugs Antitumor agents Apoptosis Cancer Care and treatment Cell activation Cell Biology Cell death Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Diagnosis Dosage and administration Drug Resistance, Neoplasm Erythropoietin - genetics Extracellular signal-regulated kinase Gene Expression Regulation, Neoplastic - drug effects Growth factors Health aspects Human Genetics Humans Imatinib Internal Medicine Kinases Medicine Medicine & Public Health Mutation Neoplasm Staging Nerve growth factor Nerve Growth Factor - genetics Neuroblastoma Neuroblastoma - drug therapy Neuroblastoma - genetics Neuroblastoma - pathology Observations Oncology Patients Protein Kinase Inhibitors - pharmacology Relapse Risk factors Signal transduction Signal Transduction - drug effects Survival Analysis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!